

Real world data of people living with HIV-2: experience of 7 London clinics

Stephanie Tyler¹, Sarah Keegan¹, Chon Lam², Yemi Daramola³, Nadine Collins⁴, Abhishek Katiyar⁵, Donna Johnson⁶, Carol Jones⁷, Poonam Ranchan⁷, Ranjana Jayaprakash⁷, Ranjababu Kulasegaram¹

¹Guy's and St Thomas' NHS Foundation Trust, ²St George's Hospital, ³Chelsea and Westminster Hospital, ⁴Lewisham and Greenwich Hospital, ⁵Royal Free Hospital, ⁶Croydon Health Services Trust, ⁷Barking, Havering and Redbridge University Hospitals NHS Trust

Background

- HIV-2 is mainly restricted to West Africa, estimated around 1-2 million people worldwide. HIV-2 prevalence is low in the UK forming the minority of people living with HIV (PLWH).
- To date, there have been no published RCTs of ART for HIV-2. Most guidelines have been developed from evidence based on cohort and observational studies.
- Certain ART do not have activity against HIV-2 and clinical impression is that there is much variation in prescribing.
- We aim to describe ART choices and virological outcomes.

Method

- A retrospective observational study was conducted using electronic medical records of all PLWH-2 and/or co-infected with HIV-1.
- A data collection tool was piloted and a collaboration was established at the HIV Pharmacist London Leads meeting.
- The target population was all PLWH who have HIV-2 +/- co-infected with HIV-1 who have attended one of the 7 London Clinics.

Results

- 67 PLWH-2 were identified. The demographics included 60% female, 85% black ethnicity, 73% heterosexual exposure risk, median age of 56 years and a mean of 10 years living with HIV.
- 56 (84%) are on ART and of those 38 (68%) are undetectable.
- Only 16 (24%) people had a baseline resistance test available on file.
- Of those on ART; 37 (66%) were on a PI or 2nd generation integrase inhibitor.
- 9 people were treatment naïve and of those 88% remain undetectable.
- The mean CD4 count was 499 with 31% having a CD4<350.


Table 1: Baseline characteristics

	HIV-2 (n=55)	HIV-1 co-infected (n=12)	Total (n=67)
HIV diagnosis date:			
- 1980-1990	1	-	1
- 1991-2000	3	5	8
- 2001-2010	18	7	25
- 2011- 2021	32	-	32
- Not known	1	-	1
N. of years living with HIV-2 (mean)	9	12	10
Sex, n (%)	M:21 (38%) F:34 (62%)	M:6 (50%) F:6 (50%)	M: 27 (40%) F:40 (60%)
Median age, years	55	59	56
Ethnicity			
Black – Caribbean, African, British, other	45	12	57
White – British, Irish, other	2	-	2
Mixed – White and Black African, White and Asian, other	1	-	1
Other	4	-	4
Not known	3	-	3
Exposure			
Sexual exposure (Heterosexual)	38	11	49
Sexual exposure (MSM)	1	1	2
Blood transfusion	1	-	1
Exposure risk contact with blood products	1	-	1
Unknown	14	-	14
Nadir CD4 (mean)	335	296	327
Most recent CD4 (mean)	495	518	499
Baseline CD8 (mean)	543	957	629
Most recent CD4/CD8 ratio (mean)	0.99	0.68	0.94

Table 2: ART summary

	HIV-2 (n=55)	HIV-1 co-infected (n=12)	Total (n=67)
On ART	47	9	56
Treatment naïve	8	1	9
Off treatment	-	1	1
Unknown	-	1	1
Mean time on ART (years)	6	12	6
Mean number of ART switches	2	3	2
Current ART			
2NRTI + PI (OD)	16	4	20
2NRTI + 2 nd gen INSTI (BIC or DTG)	15	2	17
2NRTI + RAL	3	-	3
ART containing BD DRV/RTV	5	-	5
Alternative ART	8	3	11

Figure 1: UNAIDs 90 90 90 target for PLWH-2



Conclusion

- The majority of PLWH-2 are on treatment (84%) with a high genetic barrier regimen (66%). Of those on ART 68% are undetectable.
- The majority (76%) did not have any baseline resistance testing available. Of the 9 PLWH-2 who are treatment naïve 88% remain undetectable.
- The findings are limited by small numbers and missing data.
- The results show that in this cohort the UNAIDs 90 90 90 target has not been met. To help meet the goal of ending the AIDS pandemic by 2030, new attention must be given to this neglected HIV cohort.
- With the recent publication of the BHIVA HIV-2 guideline our aim is to look at current prescribing and outcomes again in 1 year.